登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中山大学孙逸仙纪念医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06843681,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Breast mass ≥2cm, and in situ cancer pathology confirmed HER2 positive (definition: immunohistochemical results 3+ or in situ hybridization results positive);
入选标准第 2 条
Previous treatment-related toxicity should be alleviated to NCI CTCAE (version 5.0) ≤1 degree, AST and ALT≤2.5 times the upper limit of normal, total bilirubin ≤1.5 times the upper limit of normal;
入选标准第 7 条
Had received radiotherapy, chemotherapy, endocrine therapy, or was participating in any interventional drug clinical trial within 4 weeks prior to enrollment;
排除标准第 9 条
Total bilirubin (TBIL) ≤3× upper limit of normal (ULN),
入选标准第 9 条
Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (patients with liver metastasis ≤5xULN),
入选标准第 10 条
Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min;
入选标准第 11 条
White blood cell count (WBC) ≥3.0×10\^9 / L,
入选标准第 13 条
Neutrophil count (ANC) ≥1.5×10\^9 / L,
入选标准第 14 条
Platelet count (PLT) ≥70×10\^9 / L
入选标准第 15 条
Imaging examination showed at least one measurable lesion within 2 weeks before enrollment;
入选标准第 5 条
Pregnant or lactating women, women of childbearing age who refused to use effective contraception during the study period;
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06843681,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Diagnosed breast carcinoma in situ (female, 18 to 70 years old); Breast mass ≥2cm, and in situ cancer pathology confirmed HER2 positive (definition: immunohistochemical results 3+ or in situ hybridization results positive); No evidence of distant transfer; Have not received any previous cancer treatment; Imaging examination showed at least one measurable lesion within 2 weeks before enrollment; Left ventricular ejection fraction (LVEF) was measured by echocardiography ≥50%; Previous treatment-related toxicity should be alleviated to NCI CTCAE (version 5.0) ≤1 degree, AST and ALT≤2.5 times the upper limit of normal, total bilirubin ≤1.5 times the upper limit of normal; Liver and kidney function tests are basically normal: Total bilirubin (TBIL) ≤3× upper limit of normal (ULN), Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (patients with liver metastasis ≤5xULN), Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min; Adequate bone marrow functional reserve: White blood cell count (WBC) ≥3.0×10\^9 / L, Neutrophil count (ANC) ≥1.5×10\^9 / L, Platelet count (PLT) ≥70×10\^9 / L Fertile women must use contraceptives; Be able to understand the research process, voluntarily participate in the study, and sign the informed consent.排除标准:Exclusion Criteria:
Metastatic breast cancer (stage IV); History of invasive breast cancer, or prior systemic treatment to treat or prevent breast cancer; Previous or concurrent malignant diseases, except skin basal cell carcinoma or cervical cancer in situ; Patients with severe heart disease or discomfort that is not expected to tolerate chemotherapy, including but not limited to: fatal arrhythmias or higher grade atrioventricular block, unstable angina pectoris, clinically significant valvular disease, transmural myocardial infarction shown by electrocardiogram, uncontrolled hypertension; Insufficient bone marrow or kidney function, liver function impairment; Grade 2 or more severe peripheral neuropathy; Patients with thrombocytopenia, neutropenia, anemia, hypokalemia, and elevation of alanine aminotransferase or aspartate aminotransferase above CTCAE Level 1; Patients who are known to be allergic to the active ingredient or other ingredient of the investigational drug; Had received radiotherapy, chemotherapy, endocrine therapy, or was participating in any interventional drug clinical trial within 4 weeks prior to enrollment; Pregnant or lactating women, women of childbearing age who refused to use effective contraception during the study period; Any other conditions that the investigator considers the patient unfit to participate in the study, concomitant diseases or conditions that may interfere with study participation, or any serious medical disorder that may affect the safety of the subject (e.g., uncontrolled heart disease, high blood pressure, active or uncontrollable infection, active hepatitis B virus infection).
引自 ClinicalTrials.gov, NCT06843681, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06843681,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。